Navigation Links
Cipla launches 3-in-1 AIDS drug in India

Cipla has launched an innovative combination of 3 HIV/AIDS drugs, Viraday that needs to be taken just once a day for effective treatment. //

The three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person, eliminates the need for 3 separate medicines. This drug has some advantages like, it is less burdensome and it can be taken along with tuberculosis medicine, which could not be done previously.

This combination drug, that was previously available only in the U.S. and European countries, was first launched in India by Cipla on Thursday. In the U.S. and Europe this combination drug costs Rs. 52,800 a month, whereas Cipla will make it accessible at just Rs. 5,200 per month. This combination drug is less toxic than when the drugs are taken separately.

This breakthrough would improve the adherence-how faithfully patients stick to the course of treatment advised by the doctor. “This is a vital issue in HIV treatment to prevent the infection from reaching the advanced stage of AIDS,” said senior consultant in Internal Medicine at Indraprastha Apollo Hospital, Dr Nalin Nag. He said, “Viraday is very patient friendly, as it requires just one pill a day and freedom from the severe side effect of many other anti HIV drugs.”

The innovative treatment kits and the 3-in-1 pills introduced by Cipla will promote adherence and ease of use. Viraday is the most remarkable accomplishment of Cipla.

Cipla has brought down the price of HIV/AIDS drugs in international market. It supplies HIV/AIDS drugs to majority of African, South Asian, Latin American and several other developing countries.
YT
'"/>




Page: 1

Related medicine news :

1. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Cipla In India Can Manufacture Drug For Bird Flu
4. FDA Gives Preliminary Nod To Cipla And Sun Drugs
5. Ciplas HIV Drug Gets FDA Approval
6. Glaxo launches pills to help smokers quit in 7-12 weeks
7. Dr Reddy’s Laboratories launches Hyalosy
8. GlaxoSmithKline launches diabetes and cancer drugs
9. YSR launches Operation Dengue
10. Is Diabetes the Leading Cause of Kidney Failure in India
11. AIDS Disaster in India is Imminent
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: